Company intelligence / Profile preview

Serene Pharma

Uzbekistan
Ownership
Private
Employees
~874
Development stage
Other
01

Overview

Serene Pharma operates in over 5 CIS countries and was the first company to introduce iron sucrose and nutritional infusion in the Uzbek market. The company is preparing to open a second manufacturing plant that will provide 40-45% of Uzbekistan's needs for medicines.

Therapeutic areas
CardiovascularEndocrinologyGastroenterologyNeurologyInfectious DiseasesOncology
Modalities
Small moleculeBiologic
Industry
Biotech
02

Drug pipeline

2 assets

tin-117m

Unknown

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Serene Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Serene Pharma.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call